Reflex detection of ciprofloxacin resistance in Neisseria gonorrhoeae by use of the SpeeDx ResistancePlus GC assay

Darren Y.J. Lee, Melinda M. Ashcroft, Eric P.F. Chow, Michelle Sait, Vesna De Petra, Marlene Tschaepe, Sigrid Lange, George Taiaroa, Catriona S. Bradshaw, David M. Whiley, Christopher K. Fairley, Benjamin P. Howden, Marcus Y. Chen, Shivani Pasricha, Deborah A. Williamson

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)


Resistance-guided therapy (RGT) for gonorrhea may reduce unnecessary use of broad-spectrum antibiotics. When reflexed from the Aptima Combo 2 assay, the ResistancePlus GC assay demonstrated 94.8% sensitivity and 100.0% specificity for Neisseria gonorrhoeae detection. Of the 379 concordant N. gonorrhoeae-positive samples, 86.8% were found to possess the gyrA S91F mutation, which was highly predictive for ciprofloxacin resistance and stable across 3,144 publicly available N. gonorrhoeae genomes. Our work supports the feasibility of implementing RGT for gonorrhea into routine molecular workflows.

Original languageEnglish
Article numbere00089-21
Number of pages5
JournalJournal of Clinical Microbiology
Issue number5
Publication statusPublished - Apr 2021


  • Antimicrobial resistance
  • Molecular diagnostic
  • Neisseria gonorrhoeae
  • Whole-genome sequencing

Cite this